Literature DB >> 17611881

Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection.

V A Morgan1, S Kyriazi, S E Ashley, N M DeSouza.   

Abstract

BACKGROUND: Conventional T2-weighted (T2W) imaging alone has a poor sensitivity for prostate cancer detection.
PURPOSE: To evaluate combined T2W and diffusion-weighted magnetic resonance imaging (DW-MRI) versus T2W MRI alone for identifying tumor in patients with prostate cancer.
MATERIAL AND METHODS: Fifty-four consecutive patients with prostate cancer (46 stage 1 and 2, 8 stage 3) and sextant biopsies within the previous 3 months were studied. Endorectal MR images were analyzed by two radiologists (1 experienced, 1 trainee) blinded to patient information and histopathology. T2W images were scored first, followed by combined T2W and isotropic apparent diffusion coefficient (ADC) maps calculated from DW-MRI (b = 0, 300, 500, and 800 s/mm(2)). Gland apex, middle, and base for each side were scored negative, indeterminate, or positive for tumor. Imaging data for each sextant were compared with histology. Sensitivity, specificity, and interobserver agreement were calculated.
RESULTS: Sensitivity and specificity for tumor identification significantly improved from 50% and 79.6% (T2W alone, experienced observer) to 73.2% and 80.8% (P<0.001), respectively. For the trainee observer, there was no improvement (44.3% and 72% T2W alone vs. 45.1% and 69.2% T2W plus ADC maps). Interobserver agreement was moderate for T2W imaging alone (kappa 0.51) and fair for T2W plus ADC maps (kappa 0.33).
CONCLUSION: In an experienced observer, DW-MRI together with T2W imaging can significantly improve tumor identification in prostate cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17611881     DOI: 10.1080/02841850701349257

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  25 in total

Review 1.  Diffusion weighted imaging in prostate cancer.

Authors:  Cher Heng Tan; Jihong Wang; Vikas Kundra
Journal:  Eur Radiol       Date:  2010-10-09       Impact factor: 5.315

2.  PET/CT imaging of recurrent prostate cancer.

Authors:  B Scher; M Seitz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01       Impact factor: 9.236

3.  Imaging: standardizing the use of functional MRI in prostate cancer.

Authors:  Nandita M deSouza; Evis Sala
Journal:  Nat Rev Urol       Date:  2011-02-15       Impact factor: 14.432

4.  Open MR-guided high-dose-rate (HDR) prostate brachytherapy: feasibility and initial experiences open MR-guided high-dose-rate (HDR) prostate brachytherapy.

Authors:  Ferenc Lakosi; Gergely Antal; Csaba Vandulek; Arpad Kovacs; Gabor L Toller; Istvan Rakasz; Gabor Bajzik; Janaki Hadjiev; Peter Bogner; Imre Repa
Journal:  Pathol Oncol Res       Date:  2011-01-11       Impact factor: 3.201

Review 5.  Various diffusion magnetic resonance imaging techniques for pancreatic cancer.

Authors:  Meng-Yue Tang; Xiao-Ming Zhang; Tian-Wu Chen; Xiao-Hua Huang
Journal:  World J Radiol       Date:  2015-12-28

Review 6.  Multiparametric MRI in prostate cancer management.

Authors:  Linda M Johnson; Baris Turkbey; William D Figg; Peter L Choyke
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

Review 7.  The emerging role of diffusion-weighted MRI in prostate cancer management.

Authors:  Edward M Lawrence; Vincent J Gnanapragasam; Andrew N Priest; Evis Sala
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

8.  Relationship between T2 relaxation and apparent diffusion coefficient in malignant and non-malignant prostate regions and the effect of peripheral zone fractional volume.

Authors:  C J Simpkin; V A Morgan; S L Giles; S F Riches; C Parker; N M deSouza
Journal:  Br J Radiol       Date:  2013-02-20       Impact factor: 3.039

Review 9.  DW-MRI of the urogenital tract: applications in oncology.

Authors:  G Petralia; H C Thoeny
Journal:  Cancer Imaging       Date:  2010-10-04       Impact factor: 3.909

Review 10.  Multidisciplinary functional MR imaging for prostate cancer.

Authors:  Jeong Kon Kim; Yun-Jin Jang; Gyunggoo Cho
Journal:  Korean J Radiol       Date:  2009 Nov-Dec       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.